Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | RXRA | P19793 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.41 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.41 |
| ▸ | LPAR5 | Q9H1C0 | 2/20 | 0.41 |
| ▸ | KDM5A | P29375 | 2/20 | 0.40 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.40 |
| ▸ | KDM5B | Q9UGL1 | 2/20 | 0.40 |
| ▸ | PTGER1 | P34995 | 2/20 | 0.40 |
| ▸ | SCN9A | Q15858 | 3/20 | 0.40 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.39 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
| ▸ | NAAA | Q02083 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23978049 | 0.82 | MRGPRX4 (0.52) | LMNAMAPK1HTTRAB9ANR1H4 | |
| SCHEMBL2101438 | 0.76 | NAAA (0.59) | RAB9ANAAA | |
| SCHEMBL1750107 | 0.75 | KMT2A (0.47) | RAB9ARXRA | |
| SCHEMBL11964298 | 0.75 | HTT (0.57) | LMNAMAPK1HTTRAB9ARXRA | |
| SCHEMBL1750158 | 0.75 | LMNA (0.57) | LMNAMAPK1HTTRAB9ALPAR1 | |
| SCHEMBL22283732 | 0.74 | IDO1 (0.56) | NAAA | |
| SCHEMBL31381199 | 0.73 | ALDH1A1 (0.45) | MAOBNAAA | |
| SCHEMBL18615735 | 0.73 | NAAA (0.59) | RAB9ASCN9ANAAA | |
| SCHEMBL1749785 | 0.72 | KMT2A (0.51) | RAB9ARXRA | |
| SCHEMBL15905013 | 0.72 | PDE4D (0.57) | LMNAMAPK1HTTRAB9ALPAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8357686-B2 | Aryl-substituted polycyclic amines, method for the production thereof, and use thereof as a medicament | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2013-01-22 | — | — | US | disclosed |
| US-8163741-B2 | Use of aryl-substituted polycyclic amines as medicaments | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2012-04-24 | — | — | US | disclosed |
| US-20090258881-A1 | ARYL-SUBSTITUTED POLYCYCLIC AMINES, METHOD FOR THE PRODUCTION THEREOF, AND USE THEREOF AS A MEDICAMENT | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2009-10-15 | — | — | US | disclosed |
| US-20090258872-A1 | USE OF ARYL-SUBSTITUTED POLYCYCLIC AMINES AS MEDICAMENTS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2009-10-15 | — | — | US | disclosed |
| US-7569583-B2 | Aryl-substituted polycyclic amines, method for the production thereof, and use thereof as a medicament | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2009-08-04 | — | — | US | disclosed |
| EP-1781656-B1 | ARYL-SUBSTITUTED POLYCYCLIC AMINES, METHOD FOR THE PRODUCTION THEREOF, AND USE THEREOF AS A MEDICAMENT | SANOFI AVENTIS DEUTSCHLAND (DE) | 2007-12-19 | — | — | EP | disclosed |
| US-20070197584-A1 | ARYL-SUBSTITUTED POLYCYCLIC AMINES, METHOD FOR THE PRODUCTION THEREOF, AND USE THEREOF AS A MEDICAMENT | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-08-23 | — | — | US | disclosed |
| EP-1781656-A2 | ARYL-SUBSTITUTED POLYCYCLIC AMINES, METHOD FOR THE PRODUCTION THEREOF, AND USE THEREOF AS A MEDICAMENT | Sanofi-Aventis Deutschland GmbH (DE) | 2007-05-09 | — | — | EP | disclosed |
| WO-2006018279-A2 | ARYL-SUBSTITUTED POLYCYCLIC AMINES, METHOD FOR THE PRODUCTION THEREOF, AND USE THEREOF AS A MEDICAMENT | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2006-02-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197584-A1 | ARYL-SUBSTITUTED POLYCYCLIC AMINES, METHOD FOR THE PRODUCTION THEREOF, AND USE THEREOF AS A MEDICAMENT | PAH, NAT1, AADAT | LMNA 2122/4885MAPK1 955/4885HTT 521/4885 |
| US-20090258872-A1 | USE OF ARYL-SUBSTITUTED POLYCYCLIC AMINES AS MEDICAMENTS | AADAT, NAT1, OAT | LMNA 2280/4885MAPK1 1019/4885HTT 677/4885 |
| US-20090258881-A1 | ARYL-SUBSTITUTED POLYCYCLIC AMINES, METHOD FOR THE PRODUCTION THEREOF, AND USE THEREOF AS A MEDICAMENT | PAH, NAT1, AADAT | LMNA 2122/4885MAPK1 955/4885HTT 521/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.